Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Abstract

Revumenib led to high remission rates with a predictable safety profile in R/R <i>KMT2Ar</i> acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for these patients.